Aldagen (Durham, North Carolina) reported that the Texas Heart Institute at St. Luke's Episcopal Hospital (Houston) will be the first site for its clinical trial using Aldagen's Aldesort product to isolate a unique stem cell population as therapy for critical limb ischemia (CLI) patients.
Aldagen's clinical trial will involve 20 patients, all of whom will have bone marrow extracted. Ten patients will receive multiple injections of the bone marrow directly into muscle in the ischemic leg and 10 patients will receive multiple injections of stem cells isolated from the bone marrow using Aldesort. The patients will be monitored for up to six months with a primary endpoint at three months. Endpoints will include safety and the ability of therapy to reduce rest pain, increase skin surface oxygen pressure and improve ulcer healing.
Aldesort isolates stem cells, taken from the patient's own bone marrow, which have the potential to build new blood vessels (angiogenesis) in ischemic legs and potentially leading to improved function for CLI patients.
CardioDynamics beefs up sales staff
CardioDynamics (San Diego) said it has increased sales staff by 25% to enhance “steadily increasing“ sales it has seen throughout 2006. The company said it had an average of 49 direct, non-managing sales personnel, including 31 capital sales representatives and 18 clinical sensor sales representatives in its fourth fiscal quarter, which ended Nov. 30.
CardioDynamics reported that it had recently increased non-managing sales headcount by 12 sales personnel, or 25%, for a total of 61 direct selling representatives.
“We were very pleased to see the steady progression in sales throughout 2006, and were especially encouraged to see solid sales results from the representatives we had hired in early to mid-2006,“ said Michael Perry, CEO of CardioDynamics.“To drive continued sales growth in 2007, we decided it would be prudent to aggressively add headcount as early in our fiscal year as possible. We now have increased sales capacity to efficiently grow our top line and have taken actions to streamline our overall organization, which should lead to improved operating results.
CardioDynamics makes noninvasive diagnostic and monitoring technologies and electrodes.